Company Profile
Aptevo Therapeutics Stock Price, News & Analysis
- Ticker:
- APVO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
4.07 USD (-2.86%)
Close
Last updated: August 6, 2026
6.28M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, APVO closed down 2.86% at $4.07. No new same-company headline was identified in the current news window.
Company overview
Business overview
Aptevo Therapeutics is a biotechnology company focused on engineered immune proteins and oncology immunotherapy. Its story is built around creating differentiated immune-engagement therapies for cancer.
Geographic Base and Sector Classification
Aptevo is headquartered in the United States and listed on NASDAQ. It sits in small-cap oncology biotechnology.
Business Model Characteristics
The company depends on clinical progress, platform validation, and capital efficiency. Investors generally watch early readouts, data quality, and strategic options.
Position Within the Biotechnology Landscape
Aptevo occupies a small engineered-immunotherapy niche within biotech. The stock is catalyst-sensitive because the pipeline is narrow and the science still needs proof.
Future catalysts
Aptevo's mipletamig data gave the company a clearer story in frontline AML. The 86 percent clinical benefit rate and the absence of cytokine release syndrome are the details that matter, especially now that the company is also widening its CD3 pipeline and adding trispecific candidates.
Recent news
- 01
Aptevo Strengthens Solid Tumor Strategy with Patent Filing for Nectin-4 x PD-L1 Dual Targeting Backbone
Source: Aptevo Therapeutics
- 02
- 03
Aptevo Therapeutics Appoints Mary J. Janatpour, Ph.D., as Senior Vice President & Chief Scientific Officer
Source: Aptevo Therapeutics
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Aptevo Therapeutics (APVO)?
Aptevo Therapeutics (APVO) most recently closed at 4.07 USD, a -2.86% move versus the previous session.
What is the market cap of Aptevo Therapeutics (APVO)?
Aptevo Therapeutics currently has a market capitalization of 6.28M USD on BioPharmSignal.
What does Aptevo Therapeutics do?
Aptevo Therapeutics is a biotechnology company focused on engineered immune proteins and oncology immunotherapy. Its story is built around creating differentiated immune-engagement therapies for cancer.
On which exchange is APVO stock listed?
Aptevo Therapeutics (APVO) is associated with NASDAQ, United States, Biopharma.
What is Aptevo?
Aptevo's mipletamig data gave the company a clearer story in frontline AML.
Which conditions is Aptevo Therapeutics targeting with Aptevo?
Aptevo Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
How does Aptevo Therapeutics describe recent progress with Aptevo?
Aptevo's mipletamig data gave the company a clearer story in frontline AML.
What is Therapeutics?
Aptevo Therapeutics is a biotechnology company focused on engineered immune proteins and oncology immunotherapy.